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Background: BICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) has been recently developed
as brief, practical and universal assessment tool for cognitive impairment in MS subjects. It includes the Symbol
Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory
Test–Revised (BVMT-R) . In this study we aimed at gathering regression based normative data for the BICAMS
battery in the Italian population.
Methods: Healthy subjects were consecutively recruited among patient friends and relatives. Corrections for
demographics were calculated using multivariable linear regression models. Test-retest reliability was assessed using
the Pearson correlation coefficient.
Results: The BICAMS battery was administered to 273 healthy subjects (180 women, mean age 38.9 ± 13.0 years,
mean education 14.9 ± 3.0 years). Test-retest reliability was good for all the tests.
Conclusions: The study provided normative data of the BICAMS for the Italian population confirming good
test-retest reliability which can facilitate the use of the battery in clinical practice, also for longitudinal patient
assessments.
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Cognitive impairment (CI) affects up to 65% of multiple
sclerosis (MS) subjects, involves all the disease subtypes
and can be documented from the very beginning of the
disease [1,2]. Moreover, once established, it tends to pro-
gress over time, sometimes independently of the accu-
mulation of physical disability [1]. Beyond the effects of
physical disability, CI has an important negative impact
on patient performance in everyday activities and is the* Correspondence: mariapia.amato@unifi.it
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unless otherwise stated.main factor leading to reduced employment or un-
employment [1] in this population of young adults. CI
also affects social activity, general independence, coping,
rehabilitation progress, treatment adherence and mental
health of MS patients [3]. The neuropsychological profile
typically involves impaired complex attention and infor-
mation processing speed, episodic memory and execu-
tive functions, whereas language and general intelligence
are usually spared [1].
For this purpose, over the last decades, assessment of
MS-related CI has received growing attention and differ-
ent neuropsychological batteries have been proposed.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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peatable Battery of Neuropsychological tests (BRB-N) [4]
and the Minimal Assessment of Cognitive Function in
MS (MACFIMS) [5]. These batteries were recognized as
highly accurate in MS patients, however, their imple-
mentation in clinical practice is limited by their time-
consuming nature (respectively 45 and 90 minutes) and
the need of supervision and interpretation by experi-
enced neuropsychologists. Therefore, there has been
considerable effort over the past decade to streamline
the neuropsychological assessment in MS, by developing
brief assessment tools that can be incorporated in every-
day patient assessment. In particular, recently, a Brief
International Cognitive Assessment for MS (BICAMS)
[3,6] is recommended as an international, validated and
standardized brief cognitive test. This battery takes about
15 minutes for administration and can be used in everyday
clinical practice, even in small MS centers with few staff
members who may not have neuropsychological training
[3,6]. It could also be integrated into more detailed cog-
nitive assessments and used as a brief assessment tool
to identify patients who require a more comprehensive
evaluation by specialized personnel. The objective of the
this Italian multicentric collaborative study was to provide
BICAMS norms in the Italian population, with corrections
for gender, age and educational level, as well as to assess
test-retest reliability in our population, following recom-
mended international standards for validation [6].
Methods
Subjects
A total of 273 healthy subjects (180 women; 93 men) were
recruited from the community in ten Italian sites repre-
sentative of the whole national territory (Bari, Barletta,
Cagliari, Catania, Chieti, Florence, Lanciano, Milan,
Naples and Rome). Exclusion criteria were neurological
and major psychiatric illness, history of learning disability,
serious head trauma (causing coma and/or neuropsycho-
logical dysfunctions), alcohol or drug abuse as well as
major medical illness. All subjects had adequate vision
and hearing to undergo the tests. Two hundred and forty-
three healthy controls agreed to undergo a second assess-
ment using the same version of the test, three weeks apart.
All the participants in the study provided their informed
consent and the study was approved by the ethic commit-
tee of the University of Florence.
Neuropsychological test procedures
In each site, the subjects were examined by the same
neuropsychologist who had participated in a common
training session, in order to ensure uniform administra-
tion, data recording and scoring procedures.
Tests were administered in a standardized manner,
during daytime, in a quiet room, and in a fixed order:SDMT [4], CVLT2 first five trials [7] and BVMT-R first
three recall trials [8]. Administration of the whole bat-
tery took 13.7 ± 3.3 minutes (median value 15 minutes).
– SDMT presented a series of nine symbols, each paired
with a single digit in a key at the top of an 8.5 -1-inch
sheet. The remainder of the page presented a
pseudo-randomized sequence of symbols. Participants
responded by voicing the digit associated with each
symbol as quickly as possible. The SDMT required
both rapid information processing and visual
scanning, and to a lesser extent, working memory.
The dependent variable was the total number of
correct responses in 90 seconds.
– CVLT-II is a measure of verbal learning and
memory. The ability to learn a 16-word list (List A)
was first examined over the course of five trials.
Examiner read 16 words and asked participants to
repeat as many words as possible. The entire List A
was repeated each time. The dependent variable we
considered was the total number of words recalled
over five learning trials (Total Learning, TL).
– BVMT-R is a measure of visuospatial learning and
memory. These were tested by exposing of the
participants to a matrix of six simple abstract
designs for 10 seconds followed by an unaided
recall. Participants were asked to reproduce the
designs using paper and pencil, taking as much time
as needed for reproduction. Each design received a
score 0, 1, or 2 based on accuracy and location
scoring criteria. The dependent variable was total
recall score across the three trials.
This is the first implementation of the BICAMS in
Italy; therefore the battery was translated and culturally
adapted for the Italian population. In particular, for vis-
ual stimuli, the presence of any semantic associations to
stimuli in Italian culture and language was screened.
Moreover, the CVLT-II was forward translated from
English into Italian by a professional native-speaking
Italian translator, matching new words on word fre-
quency and appropriate similarity of meaning.
Statistical analysis
Group comparisons were assessed through the Student’s
t –test for unpaired samples, the Mann–Whitney test and
the χ2 test, when appropriate. Regression-based norms
were calculated following the previously described pro-
cedure applied for the MACFIMS [9]. In particular, the
control group’s raw scores on each neuropsychological
measure were converted to scaled scores (M = 10, SD = 3)
using the cumulative frequency distribution of each meas-
ure. We then regressed the resulting scaled scores on age,
age-squared, gender (male = 1; female = 2), and education,
Table 1 Characteristics of the study sample
# 273 (baseline sample) 243 (re-test sample) p
Baseline Re-test
Females/Males 180/93 158/85 n.s.
Mean age: years ± SD (range) Median 38.9 ± 13.0 (18–65); 38.1 38.2 ± 13.1 (18–65); 35.3 n.s.
Mean education: years ± SD (range) Median 14.9 ± 3.1 (5–21); 16.0 14.9 ± 3.0 (5–21); 16.0 n.s.
SDMT 56.3 + 11.3 (30–91) 56.2 ± 11.6 (30–91) 60.3 + 12.0 (29–107) < 0.001
CVLT-II 56.3 + 9.0 (31–78) 56.2 ± 9.1 (31–78) 64.2 + 10.1 (34–80) < 0.001
BVMT-R 27.9 + 6.1 (11–36) 28.1 ± 6.2 (11–36) 31.3 + 5.5 (12–36) < 0.001
SD; standard deviation; ns: not significant; SDMT; Symbol Digit Modalities Test; CVLT-II; California Verbal Learning Test second edition; BVMT-R; Brief Visuospatial
Memory Test Revised.
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allowed us to consider the nonlinear relationship be-
tween age and cognition. The assumptions of regression
analysis were tested by conducting a Kolmogorov-
Smirnov test to evaluate the normality of the residuals.
The Kolmogorov-Smirnov test should not be significant.
Moreover, significant demographic predictors of scaled
scores were assessed through backward stepwise multi-
variable regression models.
The normative data can be established as it follows:
the participants’ raw test scores must be converted to
scaled scores using the raw-to-scale-score conversions
derived from the healthy controls. Next, the multiple re-
gression equations derived from the healthy controls
must be applied to compute demographically predicted
scores for each participant. These predicted scores mustTable 2 Classes of age and education
Classes of age (Years) # (%)
18-30 96 (35.1)
31-40 51 (18.7)
41-50 60 (22)
51-65 66 (24.2)
Classes of education (Years) # (%)
0-5 3 (1.1)
6-8 15 (5.5)
9-13 106 (38.8)
>13 149 (54.6)
M/F; male/female; SD; standard deviation.be then subtracted from each participant’s actual scores
and the differences divided by the standard deviation of
the controls group’s raw residuals for each measure. Fi-
nally, the resulting values can be converted to T scores
and performance on each neuropsychological measure
classified as either intact ( T > 35) or impaired ( T ≤ 35).
Test-retest reliability was assessed using the Pearson
correlation coefficient. We used alpha = 0.05 as a signifi-
cance level for including the regression coefficient in the
formula. All analyses were performed using the SPSS 20
running on Windows (SPSS, Chicago, IL, USA).Results
Tables 1 and 2 show the main characteristics of the sub-
jects who completed the test battery at baseline and re-Gender Education
≤13 >13
Males #32 14 18
Females#64 21 43
Males #20 8 12
Females#31 12 19
Males #15 8 7
Females#45 24 21
Males #26 16 10
Females#40 21 19
Gender Age years ± SD
Males #0 53.4 ± 3.9
Females#3
Males #10 47.2 ± 14.8
Females#5 42.5 ± 3.0
Males #36 39.6 ± 14.0
Females#70 40.2 ± 13.6
Males #47 37.6 ± 12.6
Females#102 37.0 + 12.2
Table 3 Raw score to scaled score conversions (baseline
sample)
Raw scores
Scaled score SDMT (#273) CVLT-II (#273) BVMRT (#273)
18 >87 >74 36
17 84-87
16 79-83 72-74
15 73-78 70-71 35
14 70-72 66-69 34
13 65-69 63-65 33
12 62-64 61-62 32
11 58-61 58-60 30-31
10 53-57 55-57 28-29
9 50-52 52-54 25-27
8 47-49 48-51 23-24
7 44-46 45-47 20-22
6 39-43 42-44 17-19
5 37-38 38-41 14-16
4 34-36 35-37 12-13
3 32-33 11
2 <32 <35 <11
BICAMS; Brief International Cognitive Assessment for Multiple Sclerosis; SDMT;
Symbol Digit Modalities Test; CVLT-II; California Verbal Learning Test second
edition; BVMT-R; Brief Visuospatial Memory Test Revised.
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and education is reported in Table 2. Classes of age were
evenly distributed; more educated subjects were pre-
dominantly represented (54.6%). Table 1 lists mean base-
line and re-test scores of the BICAMS components. InTable 4 Final regression models for BICAMS measures
Measure Predictor B Standard error B
SDMT (constant) 10.854 1.960
Age 0.040 0.092
Age2 −0.002 0.001
Gender −0.192 0.344
Education 0.060 0.055
CVLT-II (constant) 4.989 2.096
Age 0.118 0.099
Age2 −0.002 0.001
Gender 0.823 0.367
Education 0.178 0.058
BVMRT (constant) 12.694 2.310
Age −0.039 0.109
Age2 −0.001 0.001
Gender −0.671 0.405
Education 0.101 0.064
BICAMS; Brief International Cognitive Assessment for Multiple Sclerosis; SDMT; Symb
BVMT-R; Brief Visuospatial Memory Test Revised.the 243 healthy subjects who were re-assessed after
three weeks, using the same versions of the tests, mean
scores were significantly higher on all the cognitive mea-
sures (p < 0.0001).
Table 3 reports the raw to scaled scores (M = 10, SD =
3) conversion using the cumulative frequency distribu-
tion of each measure of the BICAMS. Table 4 shows the
normal control regression models for the BICAMS. All
models include age, age-squared, sex (male = 1; female =
2), and education. The Kolmogorov-Smirnov test on the
distribution of the residuals was negative for all the three
tests (p > 0.06).
These models can be used to convert MS raw scores
to regression-based T scores. For example, consider a
38-year-old female MS patients with 18 years of educa-
tion. Her predicted scaled score on the CVLT-II is
11.435 [4.989 + 38(0.118) + 382(−0.002) + 2(0.823) + 18
(0.178)]. Her actual CVLT-II score of 53 corresponds to
a scaled score of 9, according to Table 3. We then divide
the difference between her actual and predicted scaled
score (9–11.435 = −2.453) by the standard deviation of
the residual reported in Table 5 (2.842), obtaining a z
score of −0.86, which equals a T score of 41.4.
In the backward stepwise multivariable regression
models, higher age was associated with a worse perform-
ance on the three tests (SDMT: age-squared B = −0.001,
p < 0.001; CVLT-II: age-squared B = −0.001, p = 0.001;
BVMRT: age-squared B = −0.001, p < 0.001). The CVLT-
II was also influenced by education (B = 0.181, p =
0.002), with higher education associated with better per-
formance, and by gender (B = 0.847, p = 0.022), with
women performing better than men.T Standardized B Total R square
5.538
0.436 0.177
−1.472 −0.598
−0.559 −0.031
1.103 0.062 0.194
2.381
1.197 0.509
−1.635 −0.696
2.242 0.130
3.045 0.180 0.113
5.496
−0.361 −0.151
−0.459 −0.192
−1.659 −0.094
1.567 0.091 0.144
ol Digit Modalities Test; CVLT-II; California Verbal Learning Test second edition;
Table 5 Standard deviation of the residual from healthy
controls
SD residual
SDMT 2.658
CVLT-II 2.842
BVMRT 3.133
SD: Standard Deviation; SDMT; Symbol Digit Modalities Test; CVLT-II; California
Verbal Learning Test second edition; BVMT-R; Brief Visuospatial Memory
Test Revised.
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was good for all the three tests (Table 6).
Discussion
The BICAMS [3] is a well-validated, rapid and reliable
instrument, which is optimized also for small MS cen-
tres and international use. This brief cognitive tool
should not replace more comprehensive evaluation of
the cognitive function, such as MACFIMS [5] or BRB-N
[4]; instead, it will increase accessibility for cognitive as-
sessment in non-specialized centres and it can also be
integrated into more detailed cognitive assessments and
used as a brief assessment tool in all MS centres. Trans-
lation and validation of the BICAMS is ongoing in sev-
eral countries. In a recent study, BICAMS has been
validated in the Czech population. This study showed
that BICAMS accuracy and reliability are similar to
those of the MACFIMS, so that it can be recommended
for further clinical use [10]. These BICAMS psychomet-
ric characteristics have been confirmed in an Iranian
sample [11].
In the present study, we obtained normative values for
the BICAMS tests in a large Italian population represen-
tative of the whole national territory, providing correc-
tions for demographics. Our raw scores, compared with
results in the Czech sample, showed lower means for
the SDMT and CVLT-II, whereas the scores of BVMT-R
were almost overlapping. The Czech sample was youn-
ger than the currently described Italian sample (mean
age 34.0 years versus 38.9 years, respectively). However,
scores on these tests were also higher for an American
sample with a similar age range, which highlights the
need for appropriately validated national samples to take
account of translation, cultural and educational differ-
ences [6]. These results highlight the subtle linguisticTable 6 Test-retest reliability of the BICAMS tests
Test r p
CVLT-II 0,763 < 0.001
SDMT 0,815 < 0.001
BVMT-R 0,744 < 0.001
BICAMS; Brief International Cognitive Assessment for Multiple Sclerosis; SDMT;
Symbol Digit Modalities Test; CVLT-II; California Verbal Learning Test second
edition; BVMT-R; Brief Visuospatial Memory Test Revised.and cultural differences that occur when tests are trans-
lated and the importance of national validation data.
Comparing our current data for the SDMT with Italian
normative data for the BRB [12] we found that mean
scores of SDMT in the present study were higher (56.3 vs
50.9). This may be due to younger age of the subjects in-
cluded in the present study (p < 0.05).
It is noteworthy that our study confirmed good test-
retest reliability of the BICAMS tests which is an es-
sential requirement in longitudinal assessments of the
patients. In this respect, test-retest reliability was higher
(r = 0.815) for the SDMT, which is in line with previous
reports [13]. It has to be noted that high reliability
would be likely due to practice effects with the same
form tested. This finding should be confirmed using al-
ternate forms of the tests. [14].
Our sample tended to include mostly young and
middle-aged subjects with higher educational levels.
Therefore, the demographic corrections may be not be
precise for older subjects with less education; however
this group tend to be less represented in an MS clinical
population.
Conclusions
In conclusion, our results provide BICAMS norms for use
with an Italian population and provide evidence for the ro-
bust psychometric properties of the BICAMS scales in a
fourth national population. The battery was completed
with a median time of 15 minutes, confirming that it is a
brief tool appropriate for a broad range of clinical and re-
search uses. We have also reported the largest test-retest
sample data for BICAMS, which affirms its suitability for
longitudinal assessment. The next step in the validation
process will be the comparison of results obtained in our
healthy population with those of an Italian MS sample, in
order to evaluate the criterion-related validity of the
BICAMS.
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